EAST END GROUP, LLC

Lobbying for SEQIRUS · Develop and manufacture influenza vaccines.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $45,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

Legislatives issues related to pandemic preparedness and response. Drug pricing reform. Reauthorization of the Pandemic and All-Hazards Preparedness Act. Funding for pandemic influenza in the LHHS Appropriations bill. Regulatory issues related to development and procurement of pandemic influenza vaccines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.